Acorda Therapeutics Inc (ACOR) Major Shareholder Scopia Capital Management Lp Sells 43,801 Shares

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 43,801 shares of the firm’s stock in a transaction dated Thursday, December 6th. The stock was sold at an average price of $18.58, for a total transaction of $813,822.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Scopia Capital Management Lp also recently made the following trade(s):

  • On Thursday, November 29th, Scopia Capital Management Lp sold 50,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $20.20, for a total transaction of $1,010,000.00.
  • On Monday, December 3rd, Scopia Capital Management Lp sold 225,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $20.51, for a total transaction of $4,614,750.00.
  • On Thursday, October 11th, Scopia Capital Management Lp sold 143,576 shares of Acorda Therapeutics stock. The stock was sold at an average price of $16.98, for a total transaction of $2,437,920.48.
  • On Tuesday, October 9th, Scopia Capital Management Lp sold 153,858 shares of Acorda Therapeutics stock. The stock was sold at an average price of $17.28, for a total transaction of $2,658,666.24.
  • On Tuesday, October 2nd, Scopia Capital Management Lp sold 32,649 shares of Acorda Therapeutics stock. The stock was sold at an average price of $18.89, for a total transaction of $616,739.61.
  • On Thursday, October 4th, Scopia Capital Management Lp sold 126,464 shares of Acorda Therapeutics stock. The stock was sold at an average price of $19.15, for a total transaction of $2,421,785.60.

NASDAQ:ACOR traded down $0.18 during mid-day trading on Friday, hitting $18.63. The stock had a trading volume of 685,916 shares, compared to its average volume of 483,365. The company has a market cap of $894.57 million, a PE ratio of 11.33 and a beta of 1.45. Acorda Therapeutics Inc has a 52 week low of $15.60 and a 52 week high of $36.35. The company has a quick ratio of 3.95, a current ratio of 4.03 and a debt-to-equity ratio of 0.57.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.15. The firm had revenue of $142.80 million for the quarter, compared to the consensus estimate of $82.74 million. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. Acorda Therapeutics’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $0.43 EPS. As a group, equities analysts anticipate that Acorda Therapeutics Inc will post 0.08 EPS for the current year.

Large investors have recently modified their holdings of the stock. NumerixS Investment Technologies Inc lifted its position in Acorda Therapeutics by 123.5% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,800 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,100 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Acorda Therapeutics during the 2nd quarter worth about $132,000. Pacer Advisors Inc. bought a new stake in shares of Acorda Therapeutics during the 3rd quarter worth about $110,000. Schroder Investment Management Group bought a new stake in shares of Acorda Therapeutics during the 3rd quarter worth about $112,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Acorda Therapeutics during the 2nd quarter worth about $218,000.

ACOR has been the topic of a number of recent research reports. BidaskClub upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 8th. Oppenheimer set a $18.00 price target on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Sunday, September 23rd. JPMorgan Chase & Co. set a $18.00 price target on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, October 31st. TheStreet downgraded shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, October 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price objective on shares of Acorda Therapeutics in a research report on Sunday, November 4th. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $26.56.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2018/12/08/acorda-therapeutics-inc-acor-major-shareholder-scopia-capital-management-lp-sells-43801-shares.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Article: Risk Tolerance and Your Investment Decisions

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit